Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 6:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 3,004 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dementia Clear all
Completed Phase 3 Interventional

Effect of LY2062430 on the Progression of Alzheimer's Disease

NCT00904683
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
LY2062430, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years and older
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
16
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2012 · Synced Oct 25, 2026, 6:05 AM EDT
Withdrawn Phase 4 Interventional

Ziprasidone vs Standard Therapy for Agitated Patients in the ED

NCT00786318
View directory record Official record
Conditions
Psychosis, Agitation, Delirium
Interventions
ziprasidone, Standard therapy
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 25, 2026, 6:05 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

NCT05399888
View directory record Official record
Conditions
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
Interventions
Diranersen, Diranersen-matching placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 80 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
36
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 25, 2026, 6:05 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Automated, Assistive, Non-Contact Sleep Quality Monitor for Individuals With Alzheimer's Disease

NCT06045988
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Sleep Disturbance
Interventions
Non-Contact Sleep Quality Monitor System
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 25, 2026, 6:05 AM EDT
Completed Not applicable Interventional Results available

Magnesium L-Threonate for the Enhancement of Learning and Memory in People With Dementia

NCT02210286
View directory record Official record
Conditions
Dementia, Alzheimer's Disease
Interventions
Magtein
Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
60 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 25, 2026, 6:05 AM EDT
Completed Phase 1 Interventional

Memesto Wearable Device for Persons With Dementia

NCT05153161
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Memesto
Device
Lead sponsor
Edgewater Safety Systems, Inc.
Industry
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 25, 2026, 6:05 AM EDT
Withdrawn Phase 2Phase 3 Interventional

AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)

NCT01211782
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
caprylic triglyceride, long-chain triglyceride
Drug
Lead sponsor
Cerecin
Industry
Eligibility
55 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2012 · Synced Oct 25, 2026, 6:05 AM EDT
Completed Phase 1 Interventional

Salsalate in Patients Mild to Moderate Alzheimer's Disease

NCT03277573
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Salsalate, Placebo
Drug
Lead sponsor
Adam Boxer
Other
Eligibility
50 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
San Diego, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 25, 2026, 6:05 AM EDT
Completed Not applicable Interventional Results available

Using Technology to Support Care Partners for Persons With Alzheimer's Disease: Tele-STELLA

NCT04627662
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Caregiver Burnout, Family Members
Interventions
Tele-STELLA
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 25, 2026, 6:05 AM EDT
Completed Phase 2 Interventional

Tricaprilin in Mild to Moderate Alzheimer's Disease

NCT00142805
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Tricaprilin, Placebo
Drug · Other
Lead sponsor
Cerecin
Industry
Eligibility
50 Years to 90 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
25
States / cities
Phoenix, Arizona • Cerritos, California • Los Alamitos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Oct 25, 2026, 6:05 AM EDT
Completed No phase listed Observational

A Study to Determine the Signs and Symptoms That Impact Daily Life of Participants With Irregular Sleep-Wake Rhythm Disorder

NCT04300569
View directory record Official record
Conditions
Irregular Sleep Wake Rhythm Disorder
Interventions
Non-interventional
Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
6
States / cities
Costa Mesa, California • San Diego, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 25, 2026, 6:05 AM EDT
Completed Phase 2 Interventional

A Study of the Novel Drug Dimebon in Patients With Huntington's Disease

NCT00497159
View directory record Official record
Conditions
Huntington's Disease
Interventions
Placebo, Dimebon
Other · Drug
Lead sponsor
Medivation, Inc.
Industry
Eligibility
29 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 25, 2026, 6:05 AM EDT
Enrolling by invitation Phase 4 Interventional

Pilot Study of StudyU for N-of-1 Trials in HFrEF Patients (N-of-1 App)

NCT07252310
View directory record Official record
Conditions
HFrEF - Heart Failure With Reduced Ejection Fraction, Heart Failure, Heart Failure, Systolic, Heart Diseases
Interventions
beta blockers, StudyU Application
Drug · Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
65 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 25, 2026, 6:05 AM EDT
Completed Phase 4 Interventional Results available

Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly

NCT01951118
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Delirium, Dementia, Amnestic, Cognitive Disorders
Interventions
Donepezil
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 95 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 25, 2026, 6:05 AM EDT
Completed Phase 1 Interventional

Study to Evaluate DNL747 in Subjects With Alzheimer's Disease

NCT03757325
View directory record Official record
Conditions
Alzheimer Disease
Interventions
DNL747, Placebo
Drug
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 25, 2026, 6:05 AM EDT
Completed Phase 1 Interventional Results available

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

NCT01193608
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AAB-003 (PF-05236812), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 89 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
23
States / cities
Escondido, California • Hallandale, Florida • Ocala, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 25, 2026, 6:05 AM EDT
Completed Phase 3 Interventional

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

NCT03393520
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
Placebo, AVP-786
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
93
States / cities
Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 25, 2026, 6:05 AM EDT
Completed Phase 1 Interventional Results available

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

NCT01369225
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AAB-003 (PF-05236812)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 90 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
15
States / cities
Hallandale, Florida • Ocala, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 25, 2026, 6:05 AM EDT
Terminated No phase listed Observational

Identifying Novel Aging Targets for Treatment of Delirium

NCT03682874
View directory record Official record
Conditions
Delirium, Dementia Alzheimers, Respiratory Failure
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 25, 2026, 6:05 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

NCT06079190
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
GSK4527226, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 85 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
21
States / cities
San Diego, California • Lake Mary, Florida • Lake Worth, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 25, 2026, 6:05 AM EDT
Completed Not applicable Interventional Results available

Amantadine for the Treatment of Traumatic Brain Injury Irritability and Aggression: A Multi-site Study

NCT00779324
View directory record Official record
Conditions
Brain Injury, Aggression
Interventions
Amantadine Hydrochloride, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
16 Years to 75 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
6
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Charlotte, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 25, 2026, 6:05 AM EDT
Terminated Phase 2 Interventional

Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease

NCT00021723
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AN-1792 also known as AIP-001
Biological
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
11
States / cities
Peoria, Arizona • Phoenix, Arizona • Beverly Hills, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2009 · Synced Oct 25, 2026, 6:05 AM EDT
Completed Not applicable Interventional

Improving the Quality of Dementia Care Through Innovative Redesign of the Memory Care Environment

NCT04350060
View directory record Official record
Conditions
Dementia
Interventions
Retro-fitted room with technological enhancements
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 25, 2026, 6:05 AM EDT
Completed Not applicable Interventional Results available

Palliative Care Educator

NCT04857060
View directory record Official record
Conditions
Advance Care Planning, Palliative Care, Alzheimer's Disease and Related Dementias, Doctor-patient Communication, Video Decision Aids
Interventions
ACP Educator led, video assisted discussion
Behavioral
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
11,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts • Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 25, 2026, 6:05 AM EDT